DisperSol Technologies LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2007-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.austinpx.com
Clinical Trials
2
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)PK and Dose Escalation and Expansion Study of DST-2970
Phase 1
Terminated
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2020-03-02
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- DisperSol Technologies, LLC
- Target Recruit Count
- 26
- Registration Number
- NCT04291664
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸Ochsner Clinic Foundation, New Orleans, Louisiana, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation
- First Posted Date
- 2018-08-20
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- DisperSol Technologies, LLC
- Target Recruit Count
- 25
- Registration Number
- NCT03637556
- Locations
- 🇺🇸
Weill Cornell Medicine, New York-Presbyterian Hospital, New York, New York, United States
🇹🇭King Chulalongkorn Memorial Hospital, Bangkok, Thailand
🇹🇭Thalassemia Center Faculty of Medicine Siriraj Hospital, Bangkok, Thailand
News
No news found